89bio, Inc.

NasdaqGM:ETNB 주식 보고서

시가총액: US$968.0m

89bio 미래 성장

Future 기준 확인 2/6

89bio is forecast to grow earnings and revenue by 18.3% and 81.8% per annum respectively. EPS is expected to grow by 23.3% per annum. Return on equity is forecast to be -131.1% in 3 years.

주요 정보

18.3%

수익 성장률

23.3%

EPS 성장률

Biotechs 수익 성장27.1%
매출 성장률81.8%
향후 자기자본 수익률-131.1%
애널리스트 커버리지

Good

마지막 업데이트13 Sep 2024

최근 미래 성장 업데이트

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

Jan 22
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio expects to initiate Phase 2b NASH trial in 1H21

Jan 05

수익 및 매출 성장 예측

NasdaqGM:ETNB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202626-287-320-3187
12/31/20253-274-283-3107
12/31/20241-230-196-2347
6/30/2024N/A-175-166-166N/A
3/31/2024N/A-165-139-139N/A
12/31/2023N/A-142-129-129N/A
9/30/2023N/A-127-122-122N/A
6/30/2023N/A-119-106-106N/A
3/31/2023N/A-105-87-87N/A
12/31/2022N/A-102-81-81N/A
9/30/2022N/A-104-82-82N/A
6/30/2022N/A-105-81-81N/A
3/31/2022N/A-101-86-86N/A
12/31/2021N/A-90-77-77N/A
9/30/2021N/A-76-63-63N/A
6/30/2021N/A-63-62-62N/A
3/31/2021N/A-54-54-53N/A
12/31/2020N/A-49-46-46N/A
9/30/2020N/A-56-44-43N/A
6/30/2020N/A-60-37-37N/A
3/31/2020N/A-64-29-29N/A
12/31/2019N/A-57-26-25N/A
9/30/2019N/A-44-19-19N/A
6/30/2019N/A-30-15-15N/A

애널리스트 미래 성장 예측

수입 대 저축률: ETNB is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: ETNB is forecast to remain unprofitable over the next 3 years.

고성장 수익: ETNB is forecast to remain unprofitable over the next 3 years.

수익 대 시장: ETNB's revenue (81.8% per year) is forecast to grow faster than the US market (8.9% per year).

고성장 수익: ETNB's revenue (81.8% per year) is forecast to grow faster than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ETNB is forecast to be unprofitable in 3 years.


성장 기업 발견